BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22736451)

  • 1. Clinical implications and diagnostic usefulness of correlation between soluble major histocompatibility complex class I chain-related molecule a and protumorigenic cytokines in pancreatic ductal adenocarcinoma.
    Chung HW; Jang S; Lim JB
    Cancer; 2013 Jan; 119(1):233-44. PubMed ID: 22736451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of serum levels of immune-associated molecules, uric acid and soluble MHC class I chain-related molecules A and B, as diagnostic tumor markers for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB
    Cancer Sci; 2011 Sep; 102(9):1673-9. PubMed ID: 21615621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma.
    Dima SO; Tanase C; Albulescu R; Herlea V; Chivu-Economescu M; Purnichescu-Purtan R; Dumitrascu T; Duda DG; Popescu I
    Pancreas; 2012 Oct; 41(7):1001-7. PubMed ID: 22722257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB
    J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive value of soluble major histocompatibility complex class I chain-related molecule A (MICA) levels on heart allograft rejection.
    Suárez-Alvarez B; López-Vázquez A; Díaz-Molina B; Bernardo-Rodríguez MJ; Alvarez-López R; Pascual D; Astudillo A; Martínez-Borra J; Lambert JL; González S; López-Larrea C
    Transplantation; 2006 Aug; 82(3):354-61. PubMed ID: 16906033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.
    Ghassem-Zadeh S; Gaida MM; Szanyi S; Acha-Orbea H; Frossard JL; Hinz U; Hackert T; Strobel O; Felix K
    J Transl Med; 2017 Jun; 15(1):126. PubMed ID: 28578701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma.
    Wente MN; Gaida MM; Mayer C; Michalski CW; Haag N; Giese T; Felix K; Bergmann F; Giese NA; Friess H
    Int J Oncol; 2008 Aug; 33(2):297-308. PubMed ID: 18636150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma.
    Samuels S; Ferns DM; Meijer D; van Straalen JP; Buist MR; Zijlmans HJ; Kenter GG; Jordanova ES
    Tissue Antigens; 2015 Jun; 85(6):476-83. PubMed ID: 25871737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory cytokines and angiogenic factors as potential biomarkers in South African pancreatic ductal adenocarcinoma patients: A preliminary report.
    Yako YY; Brand M; Smith M; Kruger D
    Pancreatology; 2017; 17(3):438-444. PubMed ID: 28377069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
    Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
    Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis.
    Egberts JH; Cloosters V; Noack A; Schniewind B; Thon L; Klose S; Kettler B; von Forstner C; Kneitz C; Tepel J; Adam D; Wajant H; Kalthoff H; Trauzold A
    Cancer Res; 2008 Mar; 68(5):1443-50. PubMed ID: 18316608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
    Chen HT; Cai QC; Zheng JM; Man XH; Jiang H; Song B; Jin G; Zhu W; Li ZS
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S464-74. PubMed ID: 21822553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of major histocompatibility complex class I-related chain A/B (MICA/B) in pancreatic carcinoma.
    Dambrauskas Z; Svensson H; Joshi M; Hyltander A; Naredi P; Iresjö BM
    Int J Oncol; 2014 Jan; 44(1):99-104. PubMed ID: 24173243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.
    Motoda N; Matsuda Y; Onda M; Ishiwata T; Uchida E; Naito Z
    Int J Oncol; 2011 Jan; 38(1):133-43. PubMed ID: 21109934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
    Shaw VE; Lane B; Jenkinson C; Cox T; Greenhalf W; Halloran CM; Tang J; Sutton R; Neoptolemos JP; Costello E
    Mol Cancer; 2014 May; 13():114. PubMed ID: 24884871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review.
    Yako YY; Kruger D; Smith M; Brand M
    PLoS One; 2016; 11(5):e0154016. PubMed ID: 27170998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
    Kruger D; Yako YY; Devar J; Lahoud N; Smith M
    PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
    Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma.
    Park HD; Kang ES; Kim JW; Lee KT; Lee KH; Park YS; Park JO; Lee J; Heo JS; Choi SH; Choi DW; Kim S; Lee JK; Lee SY
    Proteomics; 2012 Dec; 12(23-24):3590-7. PubMed ID: 23065739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.